INTEGRA LIFESCIENCES HOLDING (IART) Fundamental Analysis & Valuation
NASDAQ:IART • US4579852082
Current stock price
8.94 USD
+0.04 (+0.45%)
At close:
8.94 USD
0 (0%)
After Hours:
This IART fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IART Profitability Analysis
1.1 Basic Checks
- IART had positive earnings in the past year.
- IART had a positive operating cash flow in the past year.
- In multiple years IART reported negative net income over the last 5 years.
- In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of IART (-14.34%) is comparable to the rest of the industry.
- With a Return On Equity value of -49.50%, IART perfoms like the industry average, outperforming 49.47% of the companies in the same industry.
- The Return On Invested Capital of IART (4.34%) is better than 75.00% of its industry peers.
- IART had an Average Return On Invested Capital over the past 3 years of 5.05%. This is below the industry average of 9.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.34% | ||
| ROE | -49.5% | ||
| ROIC | 4.34% |
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
1.3 Margins
- IART's Operating Margin of 10.58% is fine compared to the rest of the industry. IART outperforms 79.26% of its industry peers.
- In the last couple of years the Operating Margin of IART has declined.
- IART has a Gross Margin (56.62%) which is in line with its industry peers.
- In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.58% | ||
| PM (TTM) | N/A | ||
| GM | 56.62% |
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
2. IART Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.
- The number of shares outstanding for IART has been increased compared to 1 year ago.
- IART has less shares outstanding than it did 5 years ago.
- IART has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.17, we must say that IART is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.17, IART is in line with its industry, outperforming 52.13% of the companies in the same industry.
- A Debt/Equity ratio of 1.66 is on the high side and indicates that IART has dependencies on debt financing.
- The Debt to Equity ratio of IART (1.66) is worse than 80.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.66 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.17 |
ROIC/WACC0.62
WACC6.96%
2.3 Liquidity
- A Current Ratio of 2.54 indicates that IART has no problem at all paying its short term obligations.
- The Current ratio of IART (2.54) is comparable to the rest of the industry.
- IART has a Quick Ratio of 1.46. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
- IART has a worse Quick ratio (1.46) than 60.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 1.46 |
3. IART Growth Analysis
3.1 Past
- IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.89%.
- IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.86% yearly.
- The Revenue has been growing slightly by 1.53% in the past year.
- IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.57% yearly.
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%
3.2 Future
- IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.77% yearly.
- Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 3.05% on average per year.
EPS Next Y7.01%
EPS Next 2Y7.98%
EPS Next 3Y7.77%
EPS Next 5YN/A
Revenue Next Year2.71%
Revenue Next 2Y3.05%
Revenue Next 3Y3.05%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. IART Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 4.01, the valuation of IART can be described as very cheap.
- Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 98.40% of the companies are valued more expensively.
- IART is valuated cheaply when we compare the Price/Earnings ratio to 25.23, which is the current average of the S&P500 Index.
- IART is valuated cheaply with a Price/Forward Earnings ratio of 3.75.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 99.47% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.42. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.01 | ||
| Fwd PE | 3.75 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IART is valued cheaply inside the industry as 96.81% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 6.96 |
4.3 Compensation for Growth
- IART's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.57
PEG (5Y)N/A
EPS Next 2Y7.98%
EPS Next 3Y7.77%
5. IART Dividend Analysis
5.1 Amount
- No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IART Fundamentals: All Metrics, Ratios and Statistics
8.94
+0.04 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-04 2026-05-04
Inst Owners97.52%
Inst Owner Change1.22%
Ins Owners3%
Ins Owner Change-0.02%
Market Cap696.78M
Revenue(TTM)1.64B
Net Income(TTM)-516.47M
Analysts54.12
Price Target15.81 (76.85%)
Short Float %11.18%
Short Ratio9.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.69%
Min EPS beat(2)1.67%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)4.71%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)5
Avg EPS beat(8)3.77%
EPS beat(12)6
Avg EPS beat(12)3.61%
EPS beat(16)9
Avg EPS beat(16)4.3%
Revenue beat(2)0
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)-0.75%
Revenue beat(4)1
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.01%
Revenue beat(12)2
Avg Revenue beat(12)-1.1%
Revenue beat(16)3
Avg Revenue beat(16)-0.92%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-16.36%
EPS NQ rev (3m)-17.18%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)-0.66%
Revenue NQ rev (1m)-2.62%
Revenue NQ rev (3m)-2.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.01 | ||
| Fwd PE | 3.75 | ||
| P/S | 0.43 | ||
| P/FCF | N/A | ||
| P/OCF | 13.83 | ||
| P/B | 0.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.96 |
EPS(TTM)2.23
EY24.94%
EPS(NY)2.39
Fwd EY26.69%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)0.65
OCFY7.23%
SpS20.98
BVpS13.39
TBVpS-9.06
PEG (NY)0.57
PEG (5Y)N/A
Graham Number25.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.34% | ||
| ROE | -49.5% | ||
| ROCE | 5.5% | ||
| ROIC | 4.34% | ||
| ROICexc | 4.74% | ||
| ROICexgc | 12.06% | ||
| OM | 10.58% | ||
| PM (TTM) | N/A | ||
| GM | 56.62% | ||
| FCFM | N/A |
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
ROICexc(3y)5.53%
ROICexc(5y)6.31%
ROICexgc(3y)19.84%
ROICexgc(5y)22.5%
ROCE(3y)6.39%
ROCE(5y)7.09%
ROICexgc growth 3Y-20.99%
ROICexgc growth 5Y-10.51%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-5.53%
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
F-Score4
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.66 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.33 | ||
| Cap/Depr | 62.99% | ||
| Cap/Sales | 5.85% | ||
| Interest Coverage | 2.12 | ||
| Cash Conversion | 15.51% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 1.46 | ||
| Altman-Z | 1.17 |
F-Score4
WACC6.96%
ROIC/WACC0.62
Cap/Depr(3y)66.1%
Cap/Depr(5y)55.65%
Cap/Sales(3y)5.76%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
EPS Next Y7.01%
EPS Next 2Y7.98%
EPS Next 3Y7.77%
EPS Next 5YN/A
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%
Revenue Next Year2.71%
Revenue Next 2Y3.05%
Revenue Next 3Y3.05%
Revenue Next 5YN/A
EBIT growth 1Y-5.3%
EBIT growth 3Y-16.12%
EBIT growth 5Y-4.59%
EBIT Next Year25.02%
EBIT Next 3Y12.61%
EBIT Next 5YN/A
FCF growth 1Y-401.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.06%
OCF growth 3Y-42.46%
OCF growth 5Y-24.38%
INTEGRA LIFESCIENCES HOLDING / IART Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 3 / 10 to IART.
What is the valuation status for IART stock?
ChartMill assigns a valuation rating of 7 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Undervalued.
What is the profitability of IART stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 3 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 2 / 10.